PURPOSE: Since the introduction of 68Ga-PSMA-11 PET/CT for imaging prostate cancer (PC) we have frequently observed mediastinal lymph nodes (LN) showing tracer uptake despite being classified as benign. The aim of this evaluation was to further analyze such LN. METHODS: Two patient groups with biphasic 68Ga-PSMA-11 PET/CT at 1 h and 3 h p.i. were included in this retrospective evaluation. Group A (n = 38) included patients without LN metastases, and group B (n = 43) patients with LN metastases of PC. SUV of mediastinal/paraaortal LN of group A (n = 100) were compared to SUV of LN metastases of group B (n = 91). Additionally, 22 randomly selected mediastinal and paraaortal LN of patients without PC were immunohistochemically (IHC)...
PurposeTo determine the clinical value of two novel molecular imaging techniques: 11C-choline positr...
Prostate-specific membrane antigen [4_TD$DIFF]Positron-emission tomography Prostate cancer Prostate-...
Purpose: Prostate-specific membrane antigen (PSMA) agents, such as [68Ga]Ga-PSMA-11, have an unprece...
PURPOSE Since the introduction ofGa-PSMA-11 PET/CT for imaging prostate cancer (PC) we have frequ...
Aim: To assess whether clinical prostate cancer (PCA) related factors and therapy status can predict...
68Ga-prostate-specific membrane antigen (PSMA) PET/CT is a new method to detect early nodal metastas...
PURPOSE Differentiating between prostate cancer (PC) lesions and benign structures which exhibit ...
Purpose:PET/CT with the PSMA ligand is a powerful new method for the early detection of nodal metast...
The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a...
The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a...
Purpose: Prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imagi...
The short half-life of existing prostate-specificmembraneantigen (PSMA) tracers limits their time fo...
PURPOSE: To investigate whether time-trends of enhanced [(18)F]Fluoromethylcholine ([(18)F]FCH) in l...
PURPOSE: To determine the clinical value of two novel molecular imaging techniques: (11)C-choline po...
PURPOSE Dual-time point PET/CT scanning with [68Ga]Ga-PSMA-11 in the diagnosis of prostate cancer...
PurposeTo determine the clinical value of two novel molecular imaging techniques: 11C-choline positr...
Prostate-specific membrane antigen [4_TD$DIFF]Positron-emission tomography Prostate cancer Prostate-...
Purpose: Prostate-specific membrane antigen (PSMA) agents, such as [68Ga]Ga-PSMA-11, have an unprece...
PURPOSE Since the introduction ofGa-PSMA-11 PET/CT for imaging prostate cancer (PC) we have frequ...
Aim: To assess whether clinical prostate cancer (PCA) related factors and therapy status can predict...
68Ga-prostate-specific membrane antigen (PSMA) PET/CT is a new method to detect early nodal metastas...
PURPOSE Differentiating between prostate cancer (PC) lesions and benign structures which exhibit ...
Purpose:PET/CT with the PSMA ligand is a powerful new method for the early detection of nodal metast...
The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a...
The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a...
Purpose: Prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imagi...
The short half-life of existing prostate-specificmembraneantigen (PSMA) tracers limits their time fo...
PURPOSE: To investigate whether time-trends of enhanced [(18)F]Fluoromethylcholine ([(18)F]FCH) in l...
PURPOSE: To determine the clinical value of two novel molecular imaging techniques: (11)C-choline po...
PURPOSE Dual-time point PET/CT scanning with [68Ga]Ga-PSMA-11 in the diagnosis of prostate cancer...
PurposeTo determine the clinical value of two novel molecular imaging techniques: 11C-choline positr...
Prostate-specific membrane antigen [4_TD$DIFF]Positron-emission tomography Prostate cancer Prostate-...
Purpose: Prostate-specific membrane antigen (PSMA) agents, such as [68Ga]Ga-PSMA-11, have an unprece...